Sanguinarine causes cell cyle blockade and apoptosis of human prostate carcinoma cells via modulation of cylin kinase inhibitor-cyclin-cyclin-dependent kinase machinery

Molecular Cancer Therapeutics

Volumn 3, Issue 8, 2004, Pages 933-940

  Adhami, Vaqar Mustafa ^a   Aziz, Moammir Hasan ^a   Reagan Shaw, Shannon R ^a   Nihal, Minakshi ^a   Mukhtar, Hasan ^a,b   Ahmad, Nihal ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANDROGEN; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P21; PROTEIN P27; SANGUINARINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DNA DETERMINATION; DOWN REGULATION; DRUG EFFECT; ENZYME ANALYSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA;

ALKALOIDS; ANTIOXIDANTS; APOPTOSIS; BENZOPHENANTHRIDINES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COLORING AGENTS; CYCLIN-DEPENDENT KINASES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; ISOQUINOLINES; KERATINOCYTES; MALE; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PLANT EXTRACTS; PROSTATIC NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 4444220152     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997;32:284-93.
3. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-65.
4. Mukhtar H, Ahmad N. Cancer chemoprevention: future holds in multiple agents. Toxicol Appl Pharmacol 1999;158:207-10.
5. Hail N Jr, Lotan R. Examining the role of mitochondrial respiration in vanilloid-induced apoptosis. J Natl Cancer Inst 2003;94:1281-92.
6. Chaturvedi MM, Kumar A, Darnay BG, Chainy GB, Agarwal S, Aggarwal BB. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-κB activation, lκBα phosphorylation, and degradation. J Biol Chem 1997;27:30129-34.
7. Walterova D, Ulrichova J, Valka I, Vicar J, Vavreckova C, Taborska E, et al. Benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine: biological activities and dental care applications. Acta Univ Palacki Olomuc Fac Med 1995;139:7-16.
8. Mandel ID. Chemotherapeutic agents for controlling plaque and gingivitis. J Clin Periodontol 1998;15:488-98.
9. Mandel ID. Antimicrobial mouthrinses: overview and update. J Am Dent Assoc 1994;125 Suppl 2:2S-10S.
10. Ahmad N, Gupta S, Husain MM, Heiskanen KM, Mukhtar H. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. Clin Cancer Res 2000;6:1524-8.
11. Adhami VM, Aziz MH, Mukhtar H, Ahmad N. Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin Cancer Res 2003;9:3176-82.
12. Debiton E, Madelmont JC, Legault J, Barthomeuf C. Sanguinarine-induced apoptosis is associated with early and severe cellular glutathione depletion. Cancer Chemother Pharmacol 2003;51:474-82.
13. Ding Z, Tang SC, Weerasinghe P, Yang X, Pater A, Liepins A. The alkaloid sanguinarine is effective against multidrug resistance in human cervical cells via bimodal cell death. Biochem Pharmacol 2002;63: 1415-21.
14. Weerasinghe P, Hallock S, Tang SC, Liepins A. Role of Bcl-2 family proteins and caspase-3 in sanguinarine-induced bimodal cell death. Cell Biol Toxicol 2001;17:371-81.
15. Weerasinghe P, Hallock S, Tang SC, Liepins A. Sanguinarine induces bimodal cell death in K562 but not in high Bcl-2-expressing JM1 cells. Pathol Res Pract 2001;197:717-26.
16. Weerasinghe P, Hallock S, Liepins A. Bax, Bcl-2, and NF-κB expression in sanguinarine induced bimodal cell death. Exp Mol Pathol 2001;71:89-98.
17. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 2000;6:379-92.
18. Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci USA 1997;94:2776-8.
19. Hajduch M, Havlieek L, Vesely J, Novotny R, Mihal V, Strnad M. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv Exp Med Biol 1999;457:341-53.
20. McDonald ER, El-Deiry WS. Cell cycle control as a basis for cancer drug development. Int J Oncol 2000;16:871-86.
21. Sherr CJ. Cancer cell cycles. Science 1999;274:1672-7.
22. 1-phase progression. Genes Dev 1999;13:1501-12.
23. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997;89: 1881-6.
24. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature 1999;381:643-4.
25. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995;9:935-44.
26. 1 phase progression: cycling on cue. Cell 1994;79:551-5.
27. 1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
28. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment. Mol Cancer Ther 2003;2:573-80.
29. Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur Urol 1998;34:37-41.
30. Weisburger JH. World wide prevention of cancer and other chronic diseases based on knowledge of mechanisms. Mutat Res 1998;402: 331-7.
31. Fisher DE. Pathways of apoptosis and the modulation of cell death in cancer. Hematol Oncol Clin North Am 2001;15:931-56.
32. Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, et al. Cell death: apoptosis versus necrosis. Int J Oncol 2002;21:165-70.
33. Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res 2002;8:2024-34.
34. Penn LZ. Apoptosis modulators as cancer therapeutics. Curr Opin Invest Drugs 2001;2:684-92.
35. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 2003;36:165-75.
36. King KL, Cidlowski JA. Cell cycle regulation and apoptosis. Annu Rev Physiol 1998;60:601-17.
37. Morgan SE, Kastan MB. p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 1997;71:1-25.
38. Sandhu C, Slingerland J. Deregulation of the cell cycle in cancer. Cancer Detect Prev 2000;24:107-18.
39. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
40. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995;14:3-15.
41. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000;33:261-74.
42. McDonald ER, El-Deiry WS. Cell cycle control as a basis for cancer drug development. Int J Oncol 2000;16:871-86.
43. 1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2000;8:1487-503.
44. Jones SM, Kazlauskas A. Connecting signaling and cell cycle progression in growth factor-stimulated cells. Oncogene 2000;19:5558-67.
45. Zwicker J, Muller R. Cell cycle-regulated transcription in mammalian cells. Prog Cell Cycle Res 1995;1:91-9.
46. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and CIP and INK4 inhibitors. J Mol Biol 1999;287:821-8.
47. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602:73-87.
48. Gartel AL, Serfas MS, Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996;213:138-49.
49. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:43-56.
50. Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev 1998;17:337-44.
51. 1 control in retinoblastoma gene-deficient cells independently of cdk 4 activity. Mol Cell Biol 1995; 15:2600-11.
52. 1-S-regulating genes in human cancer. Prog Cell Cycle Res 1997;3:211-20.
53. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-23.